SNS Insider Black Friday Offer
Cancer Biopsy Market

Cancer Biopsy Market Size, Share & Segment by Product (Kits and Consumables, Instruments, Services), By Type (Tissue Biopsies, Surgical Biopsies, Liquid Biopsies, Core Needle Biopsy (CNB), Needle Biopsies, Fine Needle Aspiration (FNA), Others), By Application (Breast Cancer, Prostate Cancers, Cervical Cancers, Colorectal Cancer, Pancreatic Cancers, Lung Cancers, Kidney Cancers, Blood Cancers, Ovarian Cancers, Skin Cancers, Liver Cancers), and by Regions | Global Market Forecast 2022-2028

Report Id: SNS/HC/1759 | June 2022 | Region: Global | 125 Pages

Report Scope & Overview:

The Cancer Biopsy Market Size was valued at USD 23.62 billion in 2021, and is expected to reach USD 49.45 billion by 2028, and grow at a CAGR of 11.13% over the forecast period 2022-2028.

A biopsy is a procedure that involves the removal of tissue from any part of the body in order to analysis it for disease. Some may use a needle to take a small sample of tissue, while others may surgically remove a suspected nodule or lump. Biopsies are commonly used to diagnosis cancer, but they can also be used to diagnose infections, as well as inflammatory and autoimmune illnesses. They can also be used to match organ tissue prior to transplantation and to search for evidence of organ rejection afterward.

Cancer Biopsy Market

MARKET DYNAMICS

DRIVERS

  • Oncology Disorders are becoming more common, and liquid biopsies are becoming more popular.

  • Technological Advancement

  • Inherited Oncology Disorders and Genetic Testing are becoming more well-known.

RESTRAINTS

  • Biopsy Procedure-Related Risks

  • Reimbursement possibilities that are unclear

OPPORTUNITIES

  • Various cancers are becoming more common.

CHALLENGES

  • The biopsy procedure has some limitations.

IMPACT OF COVID-19

COVID 19 has a significant impact on the medical business, particularly the market for cancer biopsies. Due to social distancing measures imposed by governments, the utilisation of healthcare services and hospital visits has severely decreased in this pandemic, resulting in patients being allowed/permitted to visit only in an emergency. Furthermore, the Centers for Medicare and Medicaid Services in the United States have classed testing as a low-priority service during this pandemic.

By Product

Kits and consumables, which are essential at various phases of biopsies, made for the greatest sales share of more than 61.0 percent in 2021. Furthermore, the segment's expansion has been aided by large expenditures made by important participants in the industry. The expansion of the market can also be ascribed to an increase in the number of patients around the world who require efficient, precise, and quick tools and kits.

Regarding gadgets, units, and consumables, disease biopsy has seen various headways. The making of viable items associated with biopsies is basic as fluid biopsy turns into a multimodal device of determination in the field of clinical malignant growth. In spite of the way that current instruments are generally used, they have various defects. The presentation of new advances, then again, is anticipated to upgrade the requirement for instruments before very long decisively.

By Type

In 2020, tissue biopsy accounted for over 80.0 percent of total revenue. It is still widely used in biopsies and in cancer diagnostics. This is due to extensive study into its safety and efficacy, which has aided in the segment's expansion.

For the next few years, advancements aimed at improving tissue biopsy processes are projected to keep the tissue biopsy segment on top. Cernostics, for example, is working on an assay that can be used to diagnose Barrett's Esophagus in cancer patients. This one-of-a-kind diagnostic technique uses digitally scanned biopsy images to aid in the identification and measurements of cellular or molecular changes within a tissue.

By Application

In 2021, breast biopsy had the highest proportion of over 15.0 percent. The most widely recognized kind of disease is bosom malignant growth. According to U.S. breast cancer statistics, about one in every eight women in the United States develops invasive breast cancer. Year the United States in 2021, an estimated 277,480 new instances of invasive breast cancer will be identified in women, with more than 40,000 new cases of non-invasive breast cancer.

Tiny examination of bosom tissue is expected for getting a conclusive determination, as well as identifying the stage and characterisation of type, in the developing number of people associated with having bosom malignant growth. This has expanded interest for needle or careful biopsies to gather tissue for tiny review, adding to fragment development.

COMPETITIVE LANDSCAPE

Some of the major players are as follows: ANGLE Plc, BD (Becton, Dickinson and Company), Biocept, Inc., Danaher, F. Hoffmann-La Roche Ltd., Hologic, Inc., Illumina, Inc., Myriad Genetics, Qiagen N.V., Thermo Fisher Scientific, Inc, and other players.

MARKET SEGMENTATION

By Product

  • Kits and Consumables
  • Instruments
  • Services

By Type

  • Tissue Biopsies
  • Surgical Biopsies
  • Liquid Biopsies
  • Core Needle Biopsy (CNB)
  • Needle Biopsies
  • Fine Needle Aspiration (FNA)
  • Others

By Application

  • Breast Cancer
  • Prostate Cancers
  • Cervical Cancers
  • Colorectal Cancer
  • Pancreatic Cancers
  • Lung Cancers
  • Kidney Cancers
  • Blood Cancers
  • Ovarian Cancers
  • Skin Cancers
  • Liver Cancers

Cancer Biopsy Market

REGIONAL ANALYSIS

In 20221, North America had the largest share of almost 40.0 percent. Throughout the projected period, the area is expected to maintain its lead, with the United States contributing significantly to regional revenue. Distributor and manufacturers in this region also want to distribute and produce new kits that are well-suited for quick diagnostic applications.

Furthermore, the profitable methods brought out by the separate government authorities are substantially favoured by the expanding acceptance of liquid biopsies across the United States. Regulation strategies for liquid biopsy-based oncology diagnostics are based on a framework developed by the US Food and Drug Administration in recent years (FDA). The proposals for advancement biomarkers and friend diagnostics, as well as endorsement points of reference, are all important for this system.

REGIONAL COVERAGE:

  • North America

    • USA

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • The Netherlands

    • Rest of Europe

  • Asia-Pacific

    • Japan

    • south Korea

    • China

    • India

    • Australia

    • Rest of Asia-Pacific

  • The Middle East & Africa

    • Israel

    • UAE

    • South Africa

    • Rest of Middle East & Africa

  • Latin America

    • Brazil

    • Argentina

    • Rest of Latin America

Cancer Biopsy Market Report Scope:
Report Attributes Details
Market Size in 2021 US$ 23.62 Billion
Market Size by 2028 US$ 49.45 Billion
CAGR CAGR of 11.13% From 2022 to 2028
Base Year 2021
Forecast Period 2022-2028
Historical Data 2017-2020
Report Scope & Coverage Market Size, Segments Analysis, Competitive  Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
Key Segments • By Product (Kits and Consumables, Instruments, Services)
• By Type (Tissue Biopsies, Surgical Biopsies, Liquid Biopsies, Core Needle Biopsy (CNB), Needle Biopsies, Fine Needle Aspiration (FNA), Others)
• By Application (Breast Cancer, Prostate Cancers, Cervical Cancers, Colorectal Cancer, Pancreatic Cancers, Lung Cancers, Kidney Cancers, Blood Cancers, Ovarian Cancers, Skin Cancers, Liver Cancers)
Regional Analysis/Coverage North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
Company Profiles ANGLE Plc, BD (Becton, Dickinson and Company), Biocept, Inc., Danaher, F. Hoffmann-La Roche Ltd., Hologic, Inc., Illumina, Inc., Myriad Genetics, Qiagen N.V., Thermo Fisher Scientific, Inc, and other players.
DRIVERS • Oncology Disorders are becoming more common, and liquid biopsies are becoming more popular.
• Technological Advancement
• Inherited Oncology Disorders and Genetic Testing are becoming more well-known.
OPPORTUNITIES • Biopsy Procedure-Related Risks
• Reimbursement possibilities that are unclear


Frequently Asked Questions (FAQ) :

Kits and consumables, which are essential at various phases of biopsies, made for the greatest sales share

North America had the largest share of almost 40.0 percent. Throughout the projected period, the area is expected to maintain its lead, with the United States contributing significantly to regional revenue.

Cancer Biopsy Market is divided into three segments and they are By Product, By Type, and By Application

Biopsy Procedure-Related Risks, Reimbursement possibilities that are unclear are the restraints of the Cancer Biopsy market.

Cancer Biopsy market is expected grow at a CAGR of 11.13% over the forecast period 2022-2028.


Table of Contents

 

1. Introduction

1.1 Market Definition

1.2 Scope

1.3 Research Assumptions

 

2. Research Methodology

 

3. Market Dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Challenges

 

4. Impact Analysis

4.1 COVID 19 Impact Analysis

4.2 Impact of Ukraine ware

 

5. Value Chain Analysis

 

6. Porter’s 5 forces model

 

7.  PEST Analysis

  

8. Cancer Biopsy Market Segmentation, By Product

8.1 Kits and Consumables

8.2 Instruments

8.3 Services

 

9. Cancer Biopsy Market Segmentation, By Type

9.1 Tissue Biopsies

9.2 Surgical Biopsies

9.3 Liquid Biopsies

9.4 Core Needle Biopsy (CNB)

9.5 Needle Biopsies

9.6 Fine Needle Aspiration (FNA)

9.7 Others

 

10. Cancer Biopsy Market Segmentation, By Application

10.1 Breast Cancer

10.2 Prostate Cancers

10.3 Cervical Cancers

10.4 Colorectal Cancer

10.5 Pancreatic Cancers

10.6 Lung Cancers

10.7 Kidney Cancers

10.8 Blood Cancers

10.9 Ovarian Cancers

10.10 Skin Cancers

10.11 Liver Cancers

 

 

11. Regional Analysis

11.1 Introduction

11.2 North America

11.2.1 USA

11.2.2 Canada

11.2.3 Mexico

11.3 Europe

11.3.1 Germany

11.3.2 UK

11.3.3 France

11.3.4 Italy

11.3.5 Spain

11.3.6 The Netherlands

11.3.7 Rest of Europe

11.4 Asia-Pacific

11.4.1 Japan

11.4.2 South Korea

11.4.3 China

11.4.4 India

11.4.5 Australia

11.4.6 Rest of Asia-Pacific

11.5 The Middle East & Africa

11.5.1 Israel

11.5.2 UAE

11.5.3 South Africa

11.5.4 Rest

11.6 Latin America

11.6.1 Brazil

11.6.2 Argentina

11.6.3 Rest of Latin America

 

12 Company Profiles

12.1 ANGLE Plc

            12.1.1 Financial

12.1.2 Products/ Services Offered

12.1.3 SWOT Analysis

12.1.4 The SNS view

12.2 BD (Becton, Dickinson and Company)

12.3 Biocept, Inc.

12.4 Danaher

12.5 F. Hoffmann-La Roche Ltd.

12.6 Hologic, Inc.

12.7 Illumina, Inc.

12.8 Myriad Genetics

12.9 Qiagen N.V.

12.10 Thermo Fisher Scientific, Inc.

 

13 Competitive Landscape

13.1 Competitive Benchmark

13.2 Market Share analysis

13.3 Recent Developments

 

14 Conclusion

 

An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.

Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.

 

The 5 steps process:

Step 1: Secondary Research:

Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.

Secondary Research

Step 2: Primary Research

When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data.  This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.

We at SNS Insider have divided Primary Research into 2 parts.

Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.

This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.

Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.

Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.

Step 3: Data Bank Validation

Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.

Step 4: QA/QC Process

After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.

Step 5: Final QC/QA Process:

This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.